Claims
- 1. An antagonist to E-selectin mediated cell adhesion wherein said antagonist is selected from a group of molecules consisting of a ligand to E-selectin containing sialyl Lex-termini, and an anti-sialyl Lex antibody.
- 2. The antagonist of claim 1 wherein said ligand is selected from a group of molecules consisting of sialyl Lex-glycoproteins, sialyl Lex-glycolipids, and sialyl Lex-chimeric glycoproteins.
- 3. The antagonist of claim 1 wherein said sialyl Lex-containing chimeric glycoprotein is soluble chimeric leukosialin protein.
- 4. The antagonist of claim 3, wherein said soluble chimeric leukosialin is chimeric soluble human leukosialin-IgG protein.
- 5. A composition containing an effective amount of one or more of the antagonists of claim 1 in addition to a carrier.
- 6. A nucleic acid sequence encoding a soluble chimeric glycoprotein.
- 7. A nucleic acid sequence encoding a soluble chimeric leukosialin-IgG.
- 8. A vector containing the nucleic acid sequence of claim 6.
- 9. A mammalian cell containing both a vector capable of directing the expression of a soluble glycoprotein and a vector capable of directing the expression of a fucosyltransferase enzyme which directs sialyl Lex synthesis.
- 10. A mammalian cell containing both a vector capable of directing the expression of a soluble chimeric leukosialin and a vector capable of directing the expression of a fucosyltransferase enzyme which directs sialy Lex synthesis.
- 11. The mammalian cell of claim 9 wherein said cell is a CHO cell.
- 12. A method of recombinantly producing glycoproteins expressing sialyl Lex termini comprising transfecting a culture of appropriate mammalian cells with both a vector which directs the expression of a soluble glycoprotein and a vector which directs the expression of a fucosyltransferase enzyme.
- 13. The method of claim 12 wherein the glycoprotein produced is soluble sialyl Lex containing leukosialin.
- 14. The method of claim 12 wherein the mammalian cells are CHO cells.
- 15. A method of inhibiting E-selectin mediated adhesion of carcinoma cells to endothelial cells comprising administering the antagonist of claim 1 to a subject.
- 16. A method of inhibiting E-selectin mediated adhesion of carcinoma cells to endothelial cells comprising administering a sialyl Lex-glycoprotein, a sialyl Lex-glycolipid, or a sialyl Lex-chimeric glycoprotein to a subject.
- 17. A method of determining the metastatic potential for a sample of carcinoma cells comprising determining the percentage of carcinoma cells which bind to E-selectin expressing cells.
- 18. The method of claim 17, wherein said E-selectin expressing cells is selected from the group consisting of activated human endothelial cells, activated mouse endothelial cells, and CHO cells expressing E-selectin.
- 19. A method of determining the metastatic potential for sample of carcinoma cells comprising determining whether an antagonist of claim 1 inhibits in a concentration dependent manner the adhesion of the carcinoma cell sample to E-selectin expressing cells.
- 20. The method of claim 19, wherein the E-selectin expressing cells are selected from the group consisting of activated human endothelial cells, activated mouse endothelial cells, and CHO cells expressing E-selectin.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application serial no. 08/073,807, filed Jun. 8, 1993, which is herein incorporated by reference in its entirety.
Government Interests
[0002] This invention was made in part with Government support under Grant Nos. CA 48737 and CA 33895 awarded by the National Institute of Health. The Government may have certain rights in the invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08369754 |
Jan 1995 |
US |
Child |
10325606 |
Dec 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08073807 |
Jun 1993 |
US |
Child |
08369754 |
Jan 1995 |
US |